Jpmorgan Chase & CO Acrivon Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Acrivon Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 33,991 shares of ACRV stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,991
Previous 5,243 548.31%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
N/A
28,748 Added 548.31%
33,991 $0
Q2 2024

Aug 12, 2024
BUY
N/A
284 Added 5.73%
5,243 $0
Q1 2024

May 10, 2024
SELL
N/A
-28,384 Reduced 85.13%
4,959 $0
Q4 2023

Feb 12, 2024
BUY
N/A
6,771 Added 25.48%
33,343 $0
Q3 2023

Nov 14, 2023
BUY
N/A
19,645 Added 283.6%
26,572 $0
Q2 2023

Aug 11, 2023
BUY
N/A
297 Added 4.48%
6,927 $0
Q1 2023

May 18, 2023
BUY
N/A
6,630 New
6,630 $0

Others Institutions Holding ACRV

# of Institutions
53
Shares Held
23.2M
Call Options Held
0
Put Options Held
0
View Full List

About Acrivon Therapeutics, Inc.

ACRV Quotes by TradingView
  • Ticker ACRV
More about ACRV
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email